This article is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Bacterial resistance to existent antibiotherapy is a perpetual internationally-recognized problem. Year after year, there is a continuous need for novel antibacterial drugs and this research and development efforts recently resulted in few new drugs or combination of drugs proposed for the use into the clinic. This review focuses on the novel US FDA approved antibacterial agents in the last two years (2018-2019). Plazomicin, eravacycline, sarecycline, omadacycline, rifamycin (2018) and imipenem, cilastatin and relebactam combination, pretomanid, lefamulin, cefiderocol (2019) are new therapeutic options. Plazomicin aminoglycoside antibiotic targets Enterobacteriaceae infections, being mainly used for the complicated urinary tract infections. The fully synthetic fluorocycline eravacycline gained approval for the complicated intra-abdominal infections. The tetracycline-derived antibiotic sarecycline might be a useful strategy for the management of non-nodular moderate to severe acne, while the other tetracycline-derived antibiotic approved, omadacycline, may be used for the patients with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. The already-known RNA-synthesis suppressor rifamycin is now also approved for noninvasive Escherichia Coli-caused travelers' diarrhea. Two combinatorial strategies were approved for complicated urinary tract infections, complicated intra-abdominal infections (imipenem, cilastatin and relebactam) and lung tuberculosis (pretomanid in combination with bedaquiline and linezolid). Lefamulin is a semisynthetic pleuromutilin antibiotic for community-acquired bacterial pneumonia, while cefiderocol, a cephalosporin antibiotic is the last antibacterial drug approved in 2019, for the use in complicated urinary tract infections. Despite of these new developments, there is an ongoing need and urgency to develop novel antibiotic strategies and drugs to overrun the bacterial resistance to antibiotics.
We identified 9 novel FDA approved antibacterial drugs: plazomicin aminoglycoside antibiotic, the fully synthetic fluorocycline eravacycline, tetracycline-derived antibiotics sarecycline and omadacycline, RNA synthesis suppressor rifamycin, two combinatorial strategies (imipenem (carbapenem antibiotic), cilastatin and relebactam and pretomanid (nitroimidazole) in combination with bedaquiline and linezolid), the semisynthetic pleuromutilin antibiotic lefamulin and cefiderocol, a cephalosporin antibiotic ( & ). These drugs are briefly discussed by FDA-approval year in the next section.
To the date of this review, 9 antibacterial drugs or combination of drugs were approved for 2018 and 2019, from a total of 107 introduced molecules. In 2018, the 5 approved antibacterial drugs or combinations of drugs represented 8.4% of the total of 59 new drugs, while in 2019 the 4 new single or combination of antibacterial drugs represented 8.33% of the 48 approved molecules. This represents a significant increase from the previous years ( ), since the number of antibacterial drugs or regimens in the past two years has doubled as compared to the two previous years.
We reviewed the total number of drugs and drug combinations (blue) and number of antibacterial drugs and drug combinations (red) approved by the US FDA in the past 17 years (2003-2019) for each individual year( , updated and modified from 17 ). There is a clear upward trend in terms of the number of antibacterial drugs approved by year.
We briefly review here the novel antibacterial agents approved by the United States Food and Drug Administration (US FDA) during the past 2 years (2018 and 2019) with the hope to further encourage the scientific community in continuing the development of new therapeutic agents for targeting the resistance of bacteria. The recently approved antibacterial drugs and drug combinations were identified using FDA’s website (https://www. accessdata.fda.gov; www.fda.gov) and Center Watch’s site (https://www.centerwatch.com/drug-information /fda-approved-drugs/).
Antibiotic stewardship has proved its efficiency, but it has its own limits and challenges 13-15 . However, the quest for new efficient molecules have to continue, remaining a pillar of anti-multidrug resistant germs strategy 16 .
Other strategy in this direction is to optimize the existing pharmaceutical arsenal, through novel combinations and new indications 8 . However, the number and efficiency of these drugs is far from covering all the existing needs and to fully combat the highly adaptive bacterial microorganisms. Moreover, pan-resistant bacteria emergence has been already described 9,10 . Other evidences further consider the non-negligible role of environmental and agriculture-related factors 11,12 .
Despite sustained efforts, the physicians are continuously confronting worldwide with the threat of bacterial resistance 1-3 . The burden on public health contributed to the creation and implementation of strategies on rational antibiotic use and on limiting the spread of resistant bacteria, the so called antibiotic stewardship 4-7 .
The run to overcome the rapid bacterial resistance started with the initial use of antibiotics. However, after decades of struggling in research and in clinical practice, this run is rather a marathon than a sprint.
Plazomicin sulfate (Zemdri) is a semisynthetic aminoglycoside bactericidal antibiotic drug, acting in asimilar manner to other aminoglycosides, by suppressing the 30S bacterial ribosomal subunit.Noteworthy, while other aminoglycosides can be inactivated by aminoglycoside-modifying enzymes, plazomicin is resistant to the action of these enzymes18.
Plazomicin was approved by FDA in June 2018, for targeting the infections with Gram-negative aerobic bacteria in the complicated urinary tract infections (cUTIs). Application was submitted for review by European Medicine Agency (EMA) in June 2018.
Plazomicin is administered intravenously (IV) every 24 hours for 4-7 days; it is primarily active against Gram-negative aerobic bacteria (e.g. Enterobacteriaceae family), to be used in patients over 18 years of age with cUTIs (including pyelonephritis), caused by susceptible Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis or Enterobacter cloacae18,19.
Plazomicin is supplied as single-dose vials in an amount of 500 mg/10 mL plazomicin base19. Administration recommendations can be found in and its dosage is personalized based on the renal function and/or therapeutic monitoring of the drug, if available19. Plazomicin might be of value in patients that have resistance to their primary treatment options or who are allergic to beta-lactam antibiotics.
The most important adverse events reported with plazomicin are: nephrotoxicity (but lower incidence of nephrotoxicity than colistin), diarrhea, hypertension, headache, nausea, vomiting, hypotension20.
Plazomicin showed to be non-inferior to meropenem within the EPIC non-inferiority trial in treatment of cUTIs and even demonstrated superior microbiological eradication (81.7% versus 70.1%; 95% confidence interval (CI) 2.7-25.7)21. Plazomicin-based combinations also demonstrated decreased disease-complications and mortality when compared to colistin-based combination in the CARE trial (23.5% versus 50%; 90% CI -0.7 to 51.2)20.
Eravacycline dihydrochloride (Xerava) is a fully synthetic bacteriostatic fluorocycline and a tetracycline-class antibacterial agent that binds bacterial 30S ribosomal subunit. Compared to other tetracyclines, it has two structural substitutions which makes the drug working on certain strains of Gram-positive and Gram-negative bacteria that usually have tetracycline-specific resistance mechanisms. Noteworthy, eravacycline can be used (at least in cell culture) to target Enterobacteriaceae, in the presence of certain beta-lactamases18,22.
Eravacycline was approved by FDA in August 2018 and by EMA in September 2018, being indicated in the complicated intra-abdominal infections22-24.
Eravacycline is administered IV in 60 min infusions, given once every 12 hours for a total of 4 to 14 days; dose is patient’s weight dependent (1mg/kg) and it is used in persons over 18 years of age with complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms identified in the prescribing information. This is the only indication of use for eravacycline at this moment, although it may be approved for other applications in the future, similar to other tetracyclines18.
The most important adverse event reported with eravacycline in clinical trials and sometimes a cause of the treatment discontinuation is the gastrointestinal (GI) upset. Other noteworthy adverse events that can appear are infusion site reactions, nausea, and vomiting18,22.
Eravacycline was compared with ertapenem and meropenem for the treatment of cIAIs in 2 non-inferiority trials (IGNITE1 and IGNITE4), with similar clinical response rates25,26.
Sarecycline hydrochloride (Seysara) is a new, narrow-spectrum tetracycline derivative. It proves antibacterial activity against skin and soft tissue pathogens, including the Cutibacterium acnes (anaerobic Gram-positive bacterium related to acne development). Similar to other tetracyclines, it possesses anti-inflammatory effects. However, it has some specific properties comparing to other tetracyclines: it seems to affect the intestinal flora less; it shows a lower rate of resistance to tetracycline-resistant Staphylococcus aureus, as well as erythromycin-resistant and clindamycin-resistant Cutibacterium acnes strains27. Sarecycline has significant effects on inflammatory lesions. However, it was also noted to show statistically significant effects on noninflammatory acneiform lesions at certain time points28.
Sarecycline was approved by FDA in October 2018, for the treatment of non-nodular moderate to severe acne. Application was also submitted for review by European Medicine Agency (EMA) in October 2018.
The drug is administrated as 1.5 mg/kg/day orally with food, in patients aged 9 and older, as a once daily antibiotic with statistically significant improvement seen as early as 3rd week. More detailed information about its administration can be found in .
In clinical trials comparing with placebo evaluating the adverse effects, nausea was reported in 3.1% of the patients treated with sarecycline versus 2.0% in patients treated with placebo; the other adverse reactions reported were found in less than 1% of female subjects treated with sarecycline: vulvovaginal mycotic infection (0.8%) and vulvovaginal candidiasis (0.6%)29.
Omadacycline (Nuzyra) is an aminomethylcycline antibiotic belonging to the tetracycline class. It inhibits 30S bacterial ribosomal subunit. Compared to other tetracycline antibiotics, omadacycline has structural modifications at the C9 and C7 positions of the core tetracycline rings, enabling ribosomal protection mechanisms and stability in the efflux pump related to resistance to the tetracycline antibiotics30.
Omadacycline was approved by FDA in October 2018 for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSI) and it is not yet approved by the EMA. It can be administered once-daily in both IV and PO formulations ().
Adverse events noted Omadacycline has warnings associated with tetracycline-class antibiotics, including: tooth discoloration, enamel hypoplasia and inhibition of bone growth in late pregnancy, infancy, or childhood up to 8 years of age. The most common adverse reactions (incidence ≥2%) seen in clinical trials of omadacycline are: nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation. Omadacycline has only been studied in patients 18 years of age or older. Omadacycline’s affinity for muscarinic M2 receptors induces a transient heart rate increases and it has no effect on the QT interval31.
A meta-analysis of randomized controlled trials revealed that the clinical efficacy of omadacycline is not inferior to that of competitor drugs in the treatment of acute bacterial infections in adult patients32.
Rifamycin (Aemcolo) is abactericidal minimally absorbed antibiotic that inhibits bacterial DNA-dependent RNA polymerase, by suppressing RNA synthesis. It is the first antibiotic engineered with Cosmo Pharmaceuticals’ Multi Matrix Technology, that enables colonic release of the active compound33.
It was approved by FDA in November 2018 for the treatment of the noninvasive strains of Escherichia coli causing travelers' diarrhea, in an orally dose of 388 mg (2 tablets) twice a day for 3 days but not when diarrhea is complicated by fever and/or bloody stools34.
The most important adverse reactions observed during the clinical trials are constipation (3.5%), headache (3.3%), abdominal pain (0.5%) & pyrexia (0.3%) with 1% of the patients discontinuing the treatment33,34.
In a randomized double-blind phase 3 study (ERASE), Rifamycin SV-MMX was found to be equally effective as ciprofloxacin and to not induce resistance in bacteria for the treatment of travellers' diarrhea35.
Recarbrio is a regimen comprising of imipenem, a penem antibacterial, cilastatin, an inhibitor of the renal dehydropeptidase and relebactam, a beta-lactamase inhibitor36.
It was approved by FDA in July 2019 for the treatment of cUTIs (including pyelonephritis) and cIAI in patients 18 years of age and older who have limited or no other treatment options available. Susceptible bacteria are Gram-negative microorganisms such as Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, aerogenes and oxytoca, Pseudomonas aeruginosa, some strains of Bacteroides and other susceptible bacteria37.
It is administered as a 30 min IV infusion: 500mg/500mg/250mg per vial (1.25g/vial): 1.25 g IV every 6h x 4-14 days (for cUTI) and 1.25 g IV every 6h x 4-14 days (for cIAI)38.
Adverse events observed with this triple combination include, but are not limited to: diarrhea, nausea, headache, vomiting, increase in transaminase, phlebitis/infusion site reactions, pyrexia, hypertension36.
Pretomanid is a nitroimidazole, a class of novel anti-bacterial agents. It was approved in August 2019 by the FDA to be used in combination with bedaquiline, which targets the adenosine triphosphate (ATP) synthase enzyme of the TB mycobacteria and linezolid, a synthetic antibiotic, the first of the oxazolidinone class, for the treatment of drug-resistant TB (lung tuberculosis). It is not yet approved by the EMA.
It is orally administered, one tablet (200 ml) taken once a day for 26 weeks for adults. Specifically, pretomanid 200 mg PO/day x 26 weeks, bedaquiline 400 mg PO/day x 2 weeks, then, 200 mg 3x/week with at least 48 h between doses for x 24 weeks (total of 26 weeks), and linezolid 1200 mg PO/day for 26 weeks39.
Adverse events reported with pretomanid include numbness and tingling of extremities, acne, anemia, nausea, vomiting, headache, increased transaminases, excess amylase in the blood, indigestion, decreased appetite, abdominal pain, rash, itching, sharp chest pain during breathing, increased gamma-glutamyl transferases, lower respiratory tract infection, cough, coughing up blood, back pain, visual impairment, low blood sugar (hypoglycemia), abnormal weight loss, diarrhea40.
The early efficacy reported in a recently published trial, showed that the pretomanid-containing regimens had a more significant early bactericidal activity than classical a HRZE regimen41. However, more research is needed before pretomanid can be validated as a promising therapy in tuberculosis42.
Lefamulin (Xenleta) is a semisynthetic pleuromutilin antibiotic that binds to the peptidyl transferase center of the 50S bacterial ribosomal subunit, inhibiting protein synthesis within bacteria43.
It was approved by FDA in August 2019 for the treatment of CABP. Lefamulin is not yet approved by EMA.
It can be administered either as an IV infusion or PO. It is used as 600 mg orally every 12 hours for 5 days or 150 mg infused IV over 60 minutes every 12 hours for 5-7 days. For additional information please consult .
As adverse events, lefamulin can prolong the QT interval (increased risk in patients with renal failure or hepatic dysfunction), produces infusion-site reactions, diarrhea, hepatic enzyme elevations, nausea, hypokalemia, insomnia, and headache. There are multiple other drugs interactions and it should not be used in pregnant women43.
FDA approval of lefamulin was based on the results of 2 randomized, controlled double-blind, noninferiority trials called LEAP 1 and LEAP 2, which enrolled 1289 adults44,45. Results of these trials demonstrated that lefamulin was as effective as moxifloxacin in the treatment of the community-acquired bacterial pneumonia43.
Cefiderocol (Fetroja) is a siderophore cephalosporin antibacterial drug that has been developed to fight a wide range of bacterial pathogens, such as the β-lactam-resistant and carbapenem-resistant orga-nisms46.
It was approved in November 2019 for the treatment of complicated urinary tract infections. It is not yet approved by EMA.
It is administered as an IV infusion, 2 gram every 8h, for 7-14 days. Cefiderocol targets a wide range of clinically relevant gram-negative bacteria, including but not limited to the Enterobacteriaceae spp, such as Enterobacter spp, Klebsiella spp, Proteus spp, Vibrio spp, Yersinia spp, Serratia marcescens, Shigella flexneri, Salmonella spp and also nonfermenting bacterial species such as Acinetobacter and Pseudomonas46-48.
As adverse effects, cefiderocol is well tolerated, with minor reports of gastrointestinal and phlebitis. This side effect profile is similar to the profile of other cephalosporin drugs49.
Clinical trials have shown that Cefiderocol's activity against bacteria non-susceptible for meropenem and Klebsiella pneumoniae carbapenemase-producing Enterobacteriales is similar or even superior to ceftazidime-avibactam. Cefiderocol is also more potent than meropenem and ceftazidime-avibactam in targeting Pseudomonas aeruginosa (against all resistance phenotypes) and Stenotrophomonas maltophilia49.
If you have any questions on Plastic Antibacterial Agent. We will give the professional answers to your questions.